Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Net Margin (2016 - 2025)

Historic Net Margin for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to 246.83%.

  • Vanda Pharmaceuticals' Net Margin fell 2376000.0% to 246.83% in Q4 2025 from the same period last year, while for Dec 2025 it was 102.02%, marking a year-over-year decrease of 925100.0%. This contributed to the annual value of 102.02% for FY2025, which is 925100.0% down from last year.
  • According to the latest figures from Q4 2025, Vanda Pharmaceuticals' Net Margin is 246.83%, which was down 2376000.0% from 40.15% recorded in Q3 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Net Margin peaked at 14.14% during Q2 2021, and registered a low of 246.83% during Q4 2025.
  • For the 5-year period, Vanda Pharmaceuticals' Net Margin averaged around 18.69%, with its median value being 2.41% (2023).
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Net Margin soared by 158500bps in 2023, and later tumbled by -2376000bps in 2025.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Net Margin stood at 10.44% in 2021, then rose by 2bps to 10.68% in 2022, then tumbled by -149bps to 5.28% in 2023, then crashed by -75bps to 9.24% in 2024, then tumbled by -2573bps to 246.83% in 2025.
  • Its last three reported values are 246.83% in Q4 2025, 40.15% for Q3 2025, and 51.7% during Q2 2025.